Akeso Announces Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II/III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer

Akeso and Summit launch a major US trial for ivonescimab in biliary tract cancer.

What the company is saying

Akeso (HKEX:9926.HK) and Summit Therapeutics (NASDAQ:SMMT) announce a clinical trial collaboration with ECOG-ACRIN to evaluate ivonescimab in advanced biliary tract cancer (BTC). The company frames this as the 7th international registrational Phase II/III trial for ivonescimab, emphasizing global expansion and the drug’s potential to become a superior first-line treatment. Executive quotes from Dr. Michelle Xia (Akeso) and Dr. Maky Zanganeh (Summit) stress confidence in ivonescimab’s clinical profile and the significance of partnering with a leading oncology group. The announcement highlights a prior Phase III study (HARMONi-GI1) in China that showed statistically significant and clinically meaningful overall survival benefits for ivonescimab plus chemotherapy versus durvalumab plus chemotherapy. The company also underscores the scale of ECOG-ACRIN’s network—over 1,400 hospitals and nearly 21,000 research professionals—and the breadth of ivonescimab’s global development program. Akeso points to a licensing agreement with Summit covering the US, Canada, South America, Europe, the Middle East, Africa, and Japan, with a total potential value of up to US$5 billion.

What the data suggests

The announcement confirms that Summit and ECOG-ACRIN will conduct a registration-enabling Phase II/III trial (EA2251, NCT07765433) for ivonescimab in advanced BTC, with US site activations expected to begin in Q4 2026. This is the second Phase III registrational study for ivonescimab in BTC and the seventh international registrational Phase II/III trial for the drug. The HARMONi-GI1 study in China previously achieved a statistically significant and clinically meaningful overall survival benefit, but detailed results will only be presented at ESMO 2026 on October 25. ECOG-ACRIN’s involvement brings a network of over 1,400 hospitals and nearly 21,000 research professionals, indicating strong institutional support. Akeso reports more than 18 Phase III studies underway globally for ivonescimab, including seven international multi-regional registrational trials and seven head-to-head studies versus PD-1/PD-L1 therapies. The out-licensing agreement with Summit covers multiple major markets and has a total potential value of up to US$5 billion, but no realised milestone payments or revenue figures are disclosed. The announcement is heavy on clinical development milestones and partnership scale, but lacks granular financial or regulatory approval data.

Analysis

The announcement is upbeat, emphasizing the scale and potential of ivonescimab's clinical program and the size of the out-licensing deal (up to US$5 billion). However, most of the key claims are forward-looking: the new Phase II/III trial (EA2251) is just beginning, and the main clinical benefit (detailed Phase III results) will not be disclosed until ESMO 2026, which is still several days away. The only realised clinical milestone is the positive OS result from the HARMONi-GI1 study in China, but no detailed data or regulatory approval is provided. The $5 billion figure is a potential, not realised, value, with no immediate earnings impact disclosed. The language around 'world's first approved' and 'first therapy to demonstrate positive results' is not substantiated by regulatory or comparative data in the release. Overall, the narrative inflates the current state of progress relative to what is actually achieved and disclosed.

Risk flags

• ●The $5 billion licensing agreement is a potential, not realised, value—actual payments depend on future clinical and regulatory milestones, which introduces significant execution risk.
• ●The new Phase II/III trial (EA2251) is only now launching in the US, so clinical and regulatory outcomes are uncertain and will take years to materialise before any commercial impact.
• ●The announcement references positive survival results from a prior Phase III study (HARMONi-GI1) in China, but does not provide detailed data or regulatory approval status, making it difficult to independently assess the magnitude or durability of the benefit.
• ●Claims of 'world's first approved' or 'first therapy to demonstrate positive results' are not substantiated with regulatory documentation or comparative data, raising the risk of overstatement.
• ●The heavy reliance on forward-looking statements and aspirational language, without immediate financial or regulatory milestones, increases the risk that near-term investor expectations may not be met.

Bottom line

Akeso and Summit Therapeutics are expanding ivonescimab’s clinical development with a major US-based Phase II/III trial in advanced biliary tract cancer, in collaboration with ECOG-ACRIN’s extensive research network. The partnership is underpinned by a licensing deal with a potential value of up to US$5 billion, but no realised payments or regulatory approvals are disclosed. The imminent presentation of detailed Phase III results from the HARMONi-GI1 study at ESMO 2026 will be the first opportunity for investors to assess the drug’s clinical impact outside of headline claims. While the scale of the clinical program and institutional partners is impressive, the announcement is largely forward-looking, and commercial or regulatory value remains unproven. Investors should focus on the forthcoming ESMO data and watch for concrete milestones such as regulatory submissions or realised licensing payments. The key takeaway is that this is a high-profile, high-potential clinical expansion, but the path to revenue and approval is still in its early stages.

Announcement summary

(HKEX:9926.HK) Akeso, Inc. and its global partner Summit Therapeutics Inc. (NASDAQ:SMMT) announced that Summit has entered into a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab in a registration-enabling Phase II/III study (EA2251, NCT07765433) in biliary tract cancer (BTC). The EA2251 study is designed to assess the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab plus chemotherapy as first-line treatment for advanced BTC. This is the 7th international registrational Phase II/III clinical trial for ivonescimab. The Phase III HARMONi-GI1 study conducted by Akeso in China previously achieved a positive overall survival (OS) result that was statistically significant and clinically meaningful for ivonescimab plus chemotherapy versus durvalumab plus chemotherapy in first-line BTC. Deirdre J. Cohen, MD, MS, Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai, is the lead investigator for EA2251. Dr. Michelle Xia, Founder, Chairwoman, President and CEO of Akeso, commented on the global expansion and potential of ivonescimab as a superior treatment for BTC. Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit Therapeutics, highlighted the importance of the collaboration with ECOG-ACRIN and the scientific interest in ivonescimab for difficult-to-treat cancers. EA2251 is the second Phase III registrational clinical study of ivonescimab in BTC. Detailed results from HARMONi-GI1 (AK112-309) will be presented at the European Society for Medical Oncology 2026 Congress (ESMO 2026) on October 25, during the Presidential Symposium from 4:30pm – 6:15pm CET (11:30am – 1:15pm EDT). ECOG-ACRIN's membership network includes over 1,400 hospitals and cancer centers and nearly 21,000 research professionals and advocates worldwide. Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody developed by Akeso and is the world's first approved bispecific antibody combining immuno-oncology and anti-angiogenesis mechanisms. Ivonescimab is also the first therapy to show positive results in a Phase III head-to-head study against pembrolizumab. Akeso is advancing more than 18 Phase III studies of ivonescimab globally, including seven international multi-regional registrational Phase III trials and seven head-to-head studies versus PD-1/PD-L1 therapies. These programs include eight registrational or Phase III studies in lung cancer and trials in other cancers such as colorectal, head and neck, biliary tract, triple-negative breast, pancreatic, and urothelial carcinoma. Akeso has out-licensed exclusive rights to develop and commercialize ivonescimab in the United States, Canada, South America, Europe, the Middle East, Africa, and Japan to Summit Therapeutics under an agreement with a total potential value of up to US$5 billion.

Disagree with this article?